Document is current
Any future updates will be listed below
-
Authors
Driban, Jeffrey B. http://orcid.org/0000-0001-6098-4273
Harkey, Matthew S.
Barbe, Mary F.
Ward, Robert J.
MacKay, James W.
Davis, Julie E.
Lu, Bing
Price, Lori Lyn
Eaton, Charles B.
Lo, Grace H.
McAlindon, Timothy E.
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR065977)
- License Information
-
More Information
Article History
Received: 22 November 2019
Accepted: 25 May 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: Institutional review boards at all OAI clinical sites and coordinating center (University of California, San Francisco) approved the study. The OAI has been approved and meets all criteria for ethical standards regarding human and animal studies defined in the 1964 Declaration of Helsinki and all amendments made after. Institutional review boards at each OAI clinical site and the OAI coordinating center (University of California, San Francisco) approved the OAI study (approval number 10–00532). All participants provided informed consent prior to participation.
: Not applicable.
: JBD, MFB, and MSH are members of the Editorial Board of BMC Musculoskeletal Disorders. JBD also reported payment for lectures from Pfizer, Inc. and consultancy from Pfizer/Lilly. TEM reported consultancy from Pfizer, Sanofi Aventis US, Kolon Tissuegene, Samumed, Seikagaku, Kiniksa Pharmaceuticals, and Anika Therapeutics. The other authors declare that they have no competing interests.
